Matthew A Cooper Selected Research

N- (1,2,3,5,6,7- hexahydro- S- indacen- 4- ylcarbamoyl)- 4- (2- hydroxy- 2- propanyl)- 2- furansulfonamide

10/2022	Interleukin-1β suppression dampens inflammatory leucocyte production and uptake in atherosclerosis.
1/2022	Aim2 suppresses cigarette smoke-induced neutrophil recruitment, neutrophil caspase-1 activation and anti-Ly6G-mediated neutrophil depletion.
1/2020	Targeting the NLRP3 Inflammasome With Inhibitor MCC950 Prevents Aortic Aneurysms and Dissections in Mice.
1/2020	NLRP3 Inflammasome Inhibition by MCC950 in Aged Mice Improves Health via Enhanced Autophagy and PPARα Activity.
1/2019	Pharmacological inhibition of the NLRP3 inflammasome reduces blood pressure, renal damage, and dysfunction in salt-sensitive hypertension.
10/2018	The Small Molecule NLRP3 Inflammasome Inhibitor MCC950 Does Not Alter Wound Healing in Obese Mice.
2/2018	Pharmacological inhibition of the NLRP3 inflammasome as a potential target for multiple sclerosis induced central neuropathic pain.
10/2017	Specific inhibition of NLRP3 in chikungunya disease reveals a role for inflammasomes in alphavirus-induced inflammation.
3/2017	The selective NLRP3-inflammasome inhibitor MCC950 reduces infarct size and preserves cardiac function in a pig model of myocardial infarction.
3/2017	Role of the NLRP3 inflammasome in a model of acute burn-induced pain.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Matthew A Cooper Research Topics

Disease

38	Infections 03/2021 - 04/2008
19	Inflammation (Inflammations) 10/2022 - 08/2014
7	Dengue (Dengue Fever) 04/2020 - 06/2011
6	Bacterial Infections (Bacterial Infection) 01/2020 - 09/2014
5	Communicable Diseases (Infectious Diseases) 12/2020 - 09/2012
5	Neoplasms (Cancer) 03/2020 - 09/2012
4	Asthma (Bronchial Asthma) 01/2022 - 12/2015
4	Autoimmune Diseases (Autoimmune Disease) 03/2015 - 04/2008
3	Atherosclerosis 10/2022 - 03/2015
3	Chronic Obstructive Pulmonary Disease (COPD) 01/2022 - 12/2015
3	Respiratory Hypersensitivity 01/2022 - 01/2017
3	Neuroinflammatory Diseases 01/2020 - 02/2018
2	Myocardial Infarction 10/2022 - 03/2017
2	Tuberculosis (Tuberculoses) 10/2022 - 01/2017
2	Obesity 01/2022 - 01/2017
2	Edema (Dropsy) 05/2021 - 03/2017
2	Malaria 03/2020 - 01/2016
2	Rupture 01/2020 - 03/2010
2	Ischemia 01/2020 - 01/2018
2	Melanoma (Melanoma, Malignant) 01/2020 - 01/2017
2	Hemolysis 01/2020 - 01/2017
2	Pneumonia (Pneumonitis) 01/2020 - 01/2017
2	Gram-Negative Bacterial Infections 01/2019 - 12/2016
2	Hypertension (High Blood Pressure) 01/2019 - 01/2017
2	Fibrosis (Cirrhosis) 01/2019 - 01/2017
2	Hyperalgesia 02/2018 - 03/2017
2	Multiple Sclerosis 02/2018 - 03/2015
2	Sepsis (Septicemia) 01/2018 - 08/2014
2	Heart Failure 01/2018 - 01/2017
2	Bacteremia 01/2018 - 05/2017
2	Breast Neoplasms (Breast Cancer) 07/2017 - 01/2017
2	Virus Diseases (Viral Diseases) 10/2016 - 03/2016
2	Cystic Fibrosis (Mucoviscidosis) 01/2016 - 06/2015
2	Human Influenza (Influenza) 12/2013 - 05/2004
1	Diphtheria 12/2021
1	Dyspepsia (Indigestion) 05/2021
1	Dysentery 05/2021

Drug/Important Bio-Agent (IBA)

28	InflammasomesIBA 10/2022 - 08/2014
21	Anti-Bacterial Agents (Antibiotics)IBA 10/2022 - 01/2013
16	Pharmaceutical PreparationsIBA 10/2019 - 10/2012
15	N- (1,2,3,5,6,7- hexahydro- S- indacen- 4- ylcarbamoyl)- 4- (2- hydroxy- 2- propanyl)- 2- furansulfonamideIBA 10/2022 - 03/2015
10	Proteins (Proteins, Gene)FDA Link 01/2020 - 06/2011
8	CytokinesIBA 10/2022 - 10/2016
6	Biomarkers (Surrogate Marker)IBA 11/2015 - 04/2008
5	Vancomycin FDA LinkGeneric 03/2021 - 03/2010
5	Peptides (Polypeptides)IBA 01/2020 - 03/2010
5	Polymyxin B (Aerosporin)FDA LinkGeneric 02/2019 - 01/2016
5	Colistin (Coly-Mycin)FDA Link 02/2019 - 10/2015
4	InterleukinsIBA 01/2019 - 08/2014
3	Monoclonal AntibodiesIBA 10/2022 - 09/2012
3	SteroidsIBA 01/2022 - 01/2017
3	NitroimidazolesIBA 12/2020 - 01/2017
3	AntibodiesIBA 04/2020 - 09/2012
3	Interleukin-6 (Interleukin 6)IBA 01/2020 - 01/2017
3	oritavancinIBA 11/2018 - 03/2014
3	NLR ProteinsIBA 02/2018 - 03/2015
3	DNA (Deoxyribonucleic Acid)IBA 01/2018 - 10/2012
3	LigandsIBA 10/2017 - 08/2014
3	VaccinesIBA 11/2015 - 12/2013
3	AntigensIBA 08/2014 - 06/2011
2	CholesterolIBA 10/2022 - 01/2020
2	NucleotidesIBA 01/2022 - 01/2017
2	Interleukin-13IBA 01/2022 - 01/2021
2	LactamsIBA 12/2021 - 06/2015
2	OvalbuminIBA 01/2021 - 01/2017
2	pretomanidIBA 12/2020 - 12/2018
2	OPC-67683IBA 12/2020 - 12/2018
2	Angiotensin IIIBA 01/2020 - 01/2017
2	GlycopeptidesIBA 11/2018 - 09/2014
2	dalbavancinIBA 11/2018 - 09/2014
2	Neutralizing AntibodiesIBA 01/2018 - 12/2013
2	EpitopesIBA 01/2018 - 12/2013
2	Polymyxins (Polymyxin)IBA 01/2018 - 02/2016
2	Interleukin-10 (Interleukin 10)IBA 05/2017 - 08/2014
2	Peptidoglycan (Murein)IBA 05/2017 - 03/2010
2	EnzymesIBA 03/2017 - 01/2017
2	Virulence Factors (Pathogenicity Factors)IBA 01/2017 - 01/2017
2	RNA (Ribonucleic Acid)IBA 01/2017 - 10/2016
2	purineIBA 01/2017 - 01/2017
2	Antimicrobial PeptidesIBA 01/2017 - 09/2012
2	ivacaftorIBA 01/2016 - 06/2015
1	Apolipoproteins E (ApoE)IBA 10/2022
1	Pyrin Domain-Containing 3 Protein NLR FamilyIBA 10/2022
1	canakinumab FDA Link 10/2022
1	Silicon Dioxide (Silica)FDA LinkGeneric 10/2022
1	SmokeIBA 01/2022
1	Interleukin-5 (Interleukin 5)IBA 01/2022
1	CC ChemokinesIBA 01/2022
1	Erythromycin (Erycette)FDA LinkGeneric 12/2021
1	Saline SolutionIBA 05/2021
1	Indomethacin (Indometacin)FDA LinkGeneric 05/2021
1	Formaldehyde (Formol)FDA Link 05/2021
1	Dinoprostone (PGE2)FDA Link 05/2021
1	CarrageenanIBA 05/2021
1	Interleukin-9 (Interleukin 9)IBA 01/2021
1	Methacholine Chloride (Methacholine)FDA Link 01/2021
1	DefensinsIBA 01/2021
1	Bronchodilator Agents (Bronchodilators)IBA 01/2021

Therapy/Procedure

17	Therapeutics 10/2022 - 09/2012
1	Traditional Medicine (Folk Remedies) 05/2021